Cargando…

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis

Detalles Bibliográficos
Autores principales:	Dhupkar, Pooja M, Yu, Ling, Gordon, Nancy, Kleinerman, Eugenie S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649291/ http://dx.doi.org/10.1186/2051-1426-3-S2-P218

Ejemplares similares

Anti‐PD‐1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
por: Dhupkar, Pooja, et al.
Publicado: (2018)

Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment
por: Kiany, Simin, et al.
Publicado: (2015)

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma
por: Yang, Yuanzheng, et al.
Publicado: (2015)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions
por: Wolf-Dennen, Kerri, et al.
Publicado: (2020)

An unusual site of metastasis: splenic metastastasis from a colon cancer
por: Efared, Boubacar, et al.
Publicado: (2016)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells
por: Naing, Aung, et al.
Publicado: (2013)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1
por: Markel, Justin E., et al.
Publicado: (2018)

Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing
por: Kleinerman, Eugenie S., et al.
Publicado: (2018)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Osteosarcoma Overview
por: Lindsey, Brock A., et al.
Publicado: (2016)

Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma
por: Rao-Bindal, Krithi, et al.
Publicado: (2011)

Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer
por: Jung, Heiyoun, et al.
Publicado: (2015)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells
por: Hollomon, Mario G, et al.
Publicado: (2013)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death
por: Hollomon, Mario G., et al.
Publicado: (2020)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
por: Liu, Xingluo, et al.
Publicado: (2003)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Mycobacteriumtuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway
por: Cao, Shuhui, et al.
Publicado: (2019)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l4ippbfpkd29a0tdpb8ldu1egh